A New Dawn in Dementia Research? Aperture Therapeutics Targets Key Brain Inflammation Protein
A significant announcement from biotech company Aperture Therapeutics is sending waves of hope through the dementia research community. The company has nominated a new development candidate, APRTX-001, a precision-engineered drug designed to tackle the neuroinflammation that drives devastating neurodegenerative diseases like Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS), with a hopeful eye toward Alzheimer’s disease. […]